Jong Chul Park1, Caroline F Pratz1, Anteneh Tesfaye2, Robert A Brodsky1, Emmanuel S Antonarakis3. 1. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD. 2. Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC. 3. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD. Electronic address: eantona1@jhmi.edu.
Abstract
BACKGROUND: Anticoagulants have been postulated to possess antitumor activity, although clinical data supporting this claim are conflicting. No definitive data exist on the clinical impact of anticoagulation therapy in patients with prostate cancer. The aim of this study was to investigate the association between therapeutic anticoagulant use and survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel chemotherapy. PATIENTS AND METHODS: We retrospectively reviewed the records of 247 consecutive patients with mCRPC who received first-line docetaxel chemotherapy between 1998 and 2010 at a single institution. Among them, 29 patients (11.7 %) received therapeutic anticoagulation (low-molecular-weight heparin [LMWH] or warfarin) for the treatment of venous thromboembolism. Univariate and multivariable Cox proportional hazards regression models were used to investigate the effect of anticoagulant use on overall survival. RESULTS: In univariate analysis, anticoagulant use was associated with improved survival (hazard ratio [HR], 0.61; P = .024). Median survival was 20.9 months in the anticoagulation group versus 17.1 months in the control group (P = .024). In multivariable analysis, anticoagulant use remained a significant predictor of survival after adjusting for other baseline prognostic factors (HR, 0.49; P = .023). When each anticoagulant was considered separately in the multivariable model, LMWH remained significantly prognostic for survival (HR, 0.48; P = .035), whereas warfarin use did not. CONCLUSIONS: Anticoagulant use (LMWH in particular) is an independent predictor of improved survival in men with mCRPC receiving docetaxel. These data provide the impetus to further explore the antitumor properties of anticoagulants in patients with prostate cancer and warrant validation in prospective studies.
BACKGROUND: Anticoagulants have been postulated to possess antitumor activity, although clinical data supporting this claim are conflicting. No definitive data exist on the clinical impact of anticoagulation therapy in patients with prostate cancer. The aim of this study was to investigate the association between therapeutic anticoagulant use and survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel chemotherapy. PATIENTS AND METHODS: We retrospectively reviewed the records of 247 consecutive patients with mCRPC who received first-line docetaxel chemotherapy between 1998 and 2010 at a single institution. Among them, 29 patients (11.7 %) received therapeutic anticoagulation (low-molecular-weight heparin [LMWH] or warfarin) for the treatment of venous thromboembolism. Univariate and multivariable Cox proportional hazards regression models were used to investigate the effect of anticoagulant use on overall survival. RESULTS: In univariate analysis, anticoagulant use was associated with improved survival (hazard ratio [HR], 0.61; P = .024). Median survival was 20.9 months in the anticoagulation group versus 17.1 months in the control group (P = .024). In multivariable analysis, anticoagulant use remained a significant predictor of survival after adjusting for other baseline prognostic factors (HR, 0.49; P = .023). When each anticoagulant was considered separately in the multivariable model, LMWH remained significantly prognostic for survival (HR, 0.48; P = .035), whereas warfarin use did not. CONCLUSIONS: Anticoagulant use (LMWH in particular) is an independent predictor of improved survival in men with mCRPC receiving docetaxel. These data provide the impetus to further explore the antitumor properties of anticoagulants in patients with prostate cancer and warrant validation in prospective studies.
Authors: M Shoji; W W Hancock; K Abe; C Micko; K A Casper; R M Baine; J N Wilcox; I Danave; D L Dillehay; E Matthews; J Contrino; J H Morrissey; S Gordon; T S Edgington; B Kudryk; D L Kreutzer; F R Rickles Journal: Am J Pathol Date: 1998-02 Impact factor: 4.307
Authors: Kostandinos Sideras; Paul L Schaefer; Scott H Okuno; Jeff A Sloan; Leila Kutteh; Tom R Fitch; Shaker R Dakhil; Ralph Levitt; Steven R Alberts; Roscoe F Morton; Kendrith M Rowland; Paul J Novotny; Charles L Loprinzi Journal: Mayo Clin Proc Date: 2006-06 Impact factor: 7.616
Authors: Clara P W Klerk; Susanne M Smorenburg; Hans-Martin Otten; Anthonie W A Lensing; Martin H Prins; Franco Piovella; Paolo Prandoni; Monique M E M Bos; Dick J Richel; Geertjan van Tienhoven; Harry R Büller Journal: J Clin Oncol Date: 2005-02-07 Impact factor: 44.544
Authors: L H Maurer; J E Herndon; D R Hollis; J Aisner; R W Carey; A T Skarin; M C Perry; W L Eaton; L L Zacharski; S Hammond; M R Green Journal: J Clin Oncol Date: 1997-11 Impact factor: 44.544
Authors: Lara A Kahale; Charbel F Matar; Ibrahim Tsolakian; Maram B Hakoum; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Lisa K Hicks; Holger Schünemann; Elie A Akl Journal: Cochrane Database Syst Rev Date: 2021-09-28
Authors: Lara A Kahale; Charbel F Matar; Maram B Hakoum; Ibrahim G Tsolakian; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Holger Schünemann; Elie A Akl Journal: Cochrane Database Syst Rev Date: 2021-12-08
Authors: Pete T T Kinnunen; Teemu J Murtola; Kirsi Talala; Kimmo Taari; Teuvo L J Tammela; Anssi Auvinen Journal: BMC Cancer Date: 2017-08-29 Impact factor: 4.430